Aripiprazole Lauroxil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications
Effect of Alkyl Chain Length on Physicochemical and Pharmacokinetic Performance of Aripiprazole Fatty Acid Prodrugs for Long-Acting Injectable Suspensions.
Journal: Pharmaceutics
Published: June 22, 2026
Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States.
Journal: Journal of managed care & specialty pharmacy
Published: April 27, 2026
Case Series: Simultaneous Use of Long-Acting Injectable Antipsychotics and Vivitrol or Long-Acting Buprenorphine in Dual Diagnosis Patients with Bipolar Disorder and Substance Use Disorders.
Journal: Psychopharmacology bulletin
Published: March 13, 2026
Beyond medication choice: Predictors of psychiatric readmission after inpatient initiation of long-acting injectable antipsychotics.
Journal: Journal of psychiatric research
Published: February 21, 2026
Serum Aripiprazole Concentrations After Inadvertent Intradeltoid Administration of Aripiprazole Lauroxil 1064 mg: A Case Report.
Journal: Therapeutic drug monitoring
Published: January 28, 2026
Impact of macrophages on the dissolution of LAI suspension prodrugs.
Journal: International journal of pharmaceutics
Published: January 11, 2026
Perimenopause as an obesogenic sensitive period: Contributions to elevated cardiovascular risk.
Journal: American journal of preventive cardiology
Published: November 22, 2025
Mechanistic Modeling of Intramuscular Administration of a Long-acting Injectable Accounting for Tissue Response At the Depot Site.
Journal: The AAPS journal
Published: July 28, 2025
Aripiprazole Lauroxil Every 2 Months for the Treatment of Adults With Schizophrenia: A Post Hoc Analysis of Efficacy by Baseline Severity of Illness From Phase 3b Clinical Trial Data.
Journal: Schizophrenia bulletin open
Published: June 09, 2025
Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia.
Journal: Neuropsychiatric disease and treatment
Published: April 22, 2025
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia.
Journal: Advances in therapy
Published: February 27, 2025
Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial.
Journal: Neuropsychiatric disease and treatment
Published: December 05, 2024
Last Updated: 09/26/2026